Areteia Therapeutics reported positive phase 3 results for dexpramipexole, an oral small molecule targeting eosinophilic asthma. The Exhale-4 trial met its primary endpoint, demonstrating significant improvements in lung function and reductions in blood eosinophil levels, suggesting an oral alternative to injectable anti-IL-5 biologics. The oral administration and favorable safety profile position dexpramipexole as a promising competitor in the multibillion-dollar asthma treatment market.